This volume covers the dramatic developments that have occurred in basic neuroscience and clinical research in cognitive neurology and dementia. It is based on the clinical approach to the patient, and provides essential knowledge that is fundamental to clinical practice.
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Although it has been known for 100 years that cognitive functioning is impaired in schizophrenia, the implications of this impairment have only recently been clearly understood. While in the past, cognitive deficits were thought to be the result of other aspects of the illness, such as poor co-operation, or as a result of the treatment of the illness, it is now known that these factors exert only a very minor influence on cognitive deficit. This book, with contributions from the major international names in the field, reviews the most recent research on the impairment of cognitive functioning in schizophrenia, covering: what it is, how wide-ranging it can be, what the clinical implications are, and how it can be treated? A detailed insight into cognitive deficit is the key to understanding why previous treatments have failed, and the key by which new treatments may change this terrible illness, treatments significantly more effective than earlier interventions.
Neuropsychiatric diseases, such as schizophrenia, Alzheimer's disease, and etc., represent a serious medical and socioeconomic problems. These diseases are often accompanied by impairments of cognitive function, e.g., abstract thinking, decision-making, attention, and several types of memory. Such deficits significantly disrupt quality of life and daily functioning of patients. Cognitive deficits in neuropsychiatric diseases are associated with alterations of brain morphology and function, and are often resistant to therapeutic interventions. In schizophrenia and related disorders, cognitive deficits are also defined as endophenotypes, i.e. measurable phenotypes linking these disaeses with discrete heritable and reproducible traits. This points to the importance of elucidating these endophenotypes in translational studies. Animal models may not mimic the full spectrum of clinical symptoms, but may act as analogies of particular behaviors or other pathological outcomes. They are useful to search for the etiology of particular psychiatric illnesses and novel therapeutics. Moreover, several behavioral tests to measure cognitive performance in rodents and other species have been implemented. The primary focus of the present topic is to provide up-to-date information on cognitive deficits of neuropsychiatric disorders, such as schizophrenia. This Research Topic also delineates future directions for translational studies aimed at developing novel treatments/interventions of cognitive disturbances.
Covering basic theory, new research, and intersections with adjacent fields, this is the first comprehensive reference work on cognitive control – our ability to use internal goals to guide thought and behavior. Draws together expert perspectives from a range of disciplines, including cognitive psychology, neuropsychology, neuroscience, cognitive science, and neurology Covers behavioral phenomena of cognitive control, neuroanatomical and computational models of frontal lobe function, and the interface between cognitive control and other mental processes Explores the ways in which cognitive control research can inform and enhance our understanding of brain development and neurological and psychiatric conditions
Social Cognition in Psychosis combines current research on phenotypes, neurobiology, and existing evidence on the assessment and treatment of various forms of psychoses. The book presents various treatment options, including assessment approaches, tools and training methods that aid in the rehabilitation of patients with psychotic disorders. Social cognition is a set of psychological processes related to understanding, recognizing, processing and appropriately using social stimuli in one's environment. Individuals with psychotic disorders consistently exhibit impairments in social cognition. As a result, social cognition has been an important target for intervention, with recent efforts trying to enhance early recovery among individuals with psychotic disorders.
This is a classic edition of Christopher Frith’s award winning book on cognitive neuropsychology and schizophrenia, which now includes a new introduction from the author. The book explores the signs and symptoms of schizophrenia using the framework of cognitive neuropsychology, looking specifically at the cognitive abnormalities that underlie these symptoms. The book won the British Psychological Society book award in 1996, and is now widely seen as a classic in the field of brain disorders. The new introduction sees the author reflect on the influence of his research and the subsequent developments in the field, more than 20 years since the book was first published.